Y-mAbs Therapeutics (YMAB) PT Lowered to $8 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts YMAB Hot Sheet
Price: $8.61 --0%
Rating Summary:
5 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
5 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Morgan Stanley analyst Michael Ulz lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $8.00 (from $17.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- First Solar (FSLR) PT Lowered to $248 at Freedom Broker
- Freedom Broker Downgrades RPC Inc. (RES) to Sell
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
